Cite
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
MLA
Maria Pouyiourou, et al. “Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial.” Nature Communications, vol. 14, no. 1, Oct. 2023, pp. 1–21. EBSCOhost, https://doi.org/10.1038/s41467-023-42400-5.
APA
Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, Gerdt Hübner, Lena Weiss, Michael Bitzer, Thomas Ernst, Philipp Schütt, Thomas Hielscher, Stefan Delorme, Martina Kirchner, Daniel Kazdal, Markus Ball, Klaus Kluck, Albrecht Stenzinger, … Alwin Krämer. (2023). Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nature Communications, 14(1), 1–21. https://doi.org/10.1038/s41467-023-42400-5
Chicago
Maria Pouyiourou, Bianca N. Kraft, Timothy Wohlfromm, Michael Stahl, Boris Kubuschok, Harald Löffler, Ulrich T. Hacker, et al. 2023. “Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial.” Nature Communications 14 (1): 1–21. doi:10.1038/s41467-023-42400-5.